biostudies-literatureUnknown3(1)Galipeau NNovartis Pharmaceuticals Corporation<h4>Background</h4>Patients with breast cancer experience a variety of disease symptoms and treatment-related side effects that can adversely affect functioning. The breast cancer experience may differ across disease stages and biomarker subtypes. This study identified relevant disease symptoms, treatment-related side effects, and physical functioning impacts in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.<h4>Methods</h4>One-on-one concept elicitation interviews were conducted with 15 patients with HR+/HER2- advanced breast cancer. Open-ended questions about patient experience with breast cancer and its treatment were drawn from a semi-structured interview guide. All interviews were audio-recorded and transcribJournal of patient-reported outcomes10https://www.ebi.ac.uk/biostudies/studies/S-EPMC6367496biostudies-literatureUnderstanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings.PMC6367496Tang DHRevicki DAKlooster BKrohe MGalipeau NCella DfalseUnderstanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings.<h4>Background</h4>Patients with breast cancer experience a variety of disease symptoms and treatment-related side effects that can adversely affect functioning. The breast cancer experience may differ across disease stages and biomarker subtypes. This study identified relevant disease symptoms, treatment-related side effects, and physical functioning impacts in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.<h4>Methods</h4>One-on-one concept elicitation interviews were conducted with 15 patients with HR+/HER2- advanced breast cancer. Open-ended questions about patient experience with breast cancer and its treatment were drawn from a semi-structured interview guide. All interviews were audio-recorded and transcrib2019-01-01T00:00:00Z2019 Feb2026-07-16T20:28:00.091Z2019-08-04T07:35:30ZS-EPMC63674963073411010.1186/s41687-019-0098-1